Kodiak (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. Our ambition is to become a significant incumbent retinal development and commercialization franchise on a global basis.
Founded in 2009, we are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular and exudative diseases, including the leading causes of blindness in elderly and working-age patients in the developed world. The KSI-301 clinical program is designed to assess KSI-301's durability, efficacy and safety in wet age-related macular degeneration, diabetic macular edema and retinal vein occlusion. These pivotal studies are anticipated to form the basis of Kodiak's initial BLA to support potential approval and commercialization in multiple diseases with a range of dosing intervals. An additional Phase 3 study with the important goal of preventing sight-threatening diabetic eye disease complications in patients with non-proliferative diabetic retinopathy is also ongoing and anticipated to be submitted in a supplemental BLA if successful. The global KSI-301 clinical program is being conducted at over 150 study sites in more than ten countries. Kodiak is developing KSI-301 and owns global rights to KSI-301.
Kodiak is also investing in its pipeline and advancing its ABC Platform™ towards improving outcomes for patients with a suboptimal anti-VEGF response, a group estimated to be as large as 30% of treated patients, with its bispecific biopolymer conjugate KSI-501. Beyond today's anti-VEGF market, Kodiak's new triplet medicines are being designed on its ABC Platform™ to combine large- and small-molecule therapeutics in an effort to bring new capabilities to treat the even higher prevalence multifactorial diseases of the retina such as dry AMD and glaucoma.
Kodiak is based in Palo Alto, California.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Presenter: Michael A Singer, M.D., Clinical Professor of Ophthalmology, University of Texas Health Science Center, and Director of Clinical Research, Medical Center Ophthalmology Associates, San Antonio, TX